Ten-Year Outcomes of Renal Tumor Radio Frequency Ablation
Ten-Year Outcomes of Renal Tumor Radio Frequency Ablation
复制标题
肾肿瘤射频消融治疗的10年疗效
DOI：
10.1016/j.juro.2018.08.045
复制
发表时间：
2019-02-01
影响因子：
6.6
通讯作者：
Cadeddu, Jeffrey A.
中科院分区：
文献类型：
--
作者：
Johnson, Brett A.;Sorokin, Igor;Cadeddu, Jeffrey A.
目的：我们回顾了10多年前接受射频消融治疗的肾肿瘤患者的长期肿瘤学结局。材料和方法：我们回顾性分析了2000年11月至2007年8月接受射频消融治疗的肾肿瘤患者的记录。对人口统计学、临床和放射学数据进行评估，以确定疾病复发的证据。有家族性肾细胞癌综合征的患者被排除在研究之外。我们用Kaplan-Meier方法计算无病生存期、无转移生存期、癌症特异性生存期和总生存期。对至少随访10年的患者进行亚组分析，以确定实际的10年生存率。结果：106例患者共112个肿瘤接受了射频消融治疗。中位随访时间为79个月（IQR 28.9-121.1），平均+/- SD肿瘤大小为2.5 +/- 0.8 cm。在97%的病例中实现了初步技术成功。复发10例。Kaplan-Meier 6年无病生存率和癌症特异性生存率分别为89%和96%。肿瘤大于3 cm的无病生存率降至68%。在至少随访10年的亚组中，实际无病生存率、癌症特异性生存率和总生存率分别为82%、94%和49%。5年后无患者复发。结论：射频消融是直径小于3 cm的肾脏小肿块的安全有效的治疗选择。我们报告了良好的肿瘤学结果和实际的10年生存数据。5年后无复发。大于3 cm的肿瘤预后明显较差。
Purpose: We reviewed long-term oncologic outcomes in patients with renal tumors treated with radio frequency ablation more than 10 years ago.Materials and Methods: We retrospectively reviewed the records of patients with renal tumors who underwent radio frequency ablation from November 2000 to August 2007. Demographic, clinical and radiological data were assessed to determine evidence of disease recurrence. Patients with familial renal cell carcinoma syndromes were excluded from study. We calculated disease-free, metastasis-free, cancer specific and overall survival with the Kaplan-Meier method. Subgroup analysis of patients who had at least 10 years followup was performed to determine actual 10-year survival. Analysis was also performed based on tumor size.Results: A total of 112 tumors in 106 patients were treated with radio frequency ablation. Median followup was 79 months (IQR 28.9-121.1) and mean +/- SD tumor size was 2.5 +/- 0.8 cm. Initial technical success was achieved in 97% of cases. There were 10 recurrences. Kaplan-Meier 6-year disease-free and cancer specific survival rates were 89% and 96%, respectively. Disease-free survival decreased to 68% for tumors greater than 3 cm. In the subgroup with at least 10-year followup the actual disease-free, cancer specific and overall survival rates were 82%, 94% and 49%, respectively. No patient experienced recurrence after 5 years.Conclusions: Radio frequency ablation is a safe and effective treatment option for small renal masses less than 3 cm in diameter. We report good oncologic outcomes with actual 10-year survival data. No recurrence developed after 5 years. Tumors greater than 3 cm have significantly poorer outcomes.